Dexrazoxane for cardioprotection in older adults with acute myeloid leukemia
| Autor: | Edward Spangenthal, Pankit Vachhani, Sarah Shin, Meir Wetzler, Jeffrey Baron, Eunice S. Wang, James E. Thompson, Evelena P. Ontiveros, Elizabeth A. Griffiths |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Anthracycline Heart failure Pharmacology lcsh:RC254-282 03 medical and health sciences 0302 clinical medicine Full Length Article Internal medicine hemic and lymphatic diseases medicine Idarubicin Cardiotoxicity Acute myeloid leukemia business.industry Daunorubicin Myeloid leukemia Adult Acute Myeloid Leukemia Hematology medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Transplantation Leukemia 030104 developmental biology 030220 oncology & carcinogenesis Dexrazoxane Mitoxantrone business medicine.drug |
| Zdroj: | Leukemia Research Reports, Vol 7, Iss C, Pp 36-39 (2017) Leukemia Research Reports |
| ISSN: | 2213-0489 |
| Popis: | Anthracyclines constitute the backbone of intensive adult acute myeloid leukemia (AML) therapy. Cardiotoxicity is one of its most serious adverse effects, and its incidence increases with cumulative dose. Dexrazoxane is a cardioprotective agent used in conjunction with anthracycline therapy. There is limited data of its usage in adult AML patients. We report the outcomes of six older adults at high risk of anthracycline-induced cardiotoxicity who received dexrazoxane during induction/re-induction therapy. Five had preserved left-ventricular function while two proceeded onto stem-cell transplantation. Additional investigation of dexrazoxane in adult leukemia therapy is warranted, particularly in older patients at highest risk for cardiovascular mortality. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|